Erste Asset Management Reduces Stake in Eli Lilly

Investment firm cuts holdings in pharmaceutical giant by over 37%

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Erste Asset Management GmbH, an investment management firm, has reduced its position in Eli Lilly and Company (NYSE: LLY) by 37.2% in the third quarter, according to a recent disclosure with the Securities & Exchange Commission. The firm now owns 64,961 shares of the pharmaceutical company's stock, valued at $47,177,000.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for developing and commercializing a broad range of medicines and therapies. Changes in institutional ownership of its stock can provide insights into investor sentiment and market dynamics surrounding the company.

The details

According to the filing, Erste Asset Management sold 38,437 shares of Eli Lilly during the third quarter, reducing its total holdings to 64,961 shares. The firm cited portfolio rebalancing and changes in investment strategy as the reasons for the reduction in its Eli Lilly position.

  • Erste Asset Management reduced its Eli Lilly holdings in the third quarter of 2026.

The players

Erste Asset Management GmbH

An investment management firm based in Europe that has reduced its stake in pharmaceutical giant Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana, known for developing and commercializing a broad range of medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Erste Asset Management's Eli Lilly holdings suggests a shift in the firm's investment strategy, potentially reflecting broader market trends or changes in the pharmaceutical industry. However, Eli Lilly remains a major player in the sector, and changes in institutional ownership do not necessarily indicate any fundamental issues with the company's performance or outlook.